Get started

PHARMA

Pharma firm SIGA cashes in on monkeypox scareNew York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox. Smallpox jabs vs monkeypox On May 19, the World Health Organization declared that vaccines used against smallpox — before the virus was eradicated in 1980 — can be used to fight monkeypox. SIGA already won approval from the US Food and Drug Administration in 2018 to distribute its oral TPOXX capsules as a treatment against smallpox even when there were no reports of confirmed or possible cases of smallpox at the time. US advances in vaccine orders Most recently, SIGA on Thursday secured another approval from the FDA for the intravenous (IV) formulation of TPOXX for patients who are unable to swallow the drug’s oral variant. SIGA said the IV formulation of TPOXX has already been cited in the recent US president’s budget request to treat a patient with monkeypox in the US. The company's shares surged 43% on Friday before paring gains to close 13% lower on the Nasdaq on Monday, and another 15.5% on Tuesday. SIGA stock remains up 26.5% over the past 5 days of trading. SIGA also stands to benefit from TPOXX’s use in Canada and Europe, where cases of moneypox were detected in recent weeks. Europe has already approved the use of TPOXX against monkeypox, cowpox, and complications from immunization with vaccinia, the company said. Growing monkeypox threat Monkeypox, first discovered in 1958, is a viral illness that first occurred in colonies of monkeys. The first human case of the virus was recorded in the Democratic Republic of Congo in 1970, according to the US Centers for Disease Control and Prevention. The virus can cause symptoms like fever, body aches, swollen lymph nodes and bumpy rashes. Cases of monkeypox have so far been reported in at least 17 countries including the US, Canada, the UK, Spain, Portugal, France, Italy and Australia. Big pharma steps in SIGA and another vaccine maker in Denmark, Bavarian Nordic (CPH:BAVA), have kept samples of smallpox virus for research purposes in case of biological warfare. The emergence of monkeypox this year prompted both companies to start mass producing vaccines against smallpox to offer protection against monkeypox. CDC officials on Monday said the US is in the process of releasing Bavarian Nordic’s Jynneos vaccine doses to fight against monkeypox. The US has stockpiled more than 1,000 doses of the vaccine and CDC officials expect to boost their purchases in the coming weeks. Bavarian Nordic’s shares on the Nasdaq Copenhagen surged to a four-month high on Monday. The Danish company on May 18 said the US government has already placed a $119 million order for the production of freeze-dried Jynneos vaccines, although deliveries are not expected until 2023 and 2024. Meanwhile, Moderna (NASDAQ:MRNA), which succeeded in developing vaccines against COVID-19, also started testing vaccines against monkeypox. The company on Tuesday said it is investigating potential vaccines against monkeypox in pre-clinical trials. No urgent need for mass vaccinations Although vaccines against monkeypox are already within reach just weeks into reports of an outbreak emerged, some experts and WHO officials say inoculations against monkeypox will not likely involve a mass campaign as the virus, unlike COVID-19, is not as contagious. Vaccinations would likely be focused only on people with close contact with infected individuals. "If a case is reported in the country, a public health SWAT team goes out, finds out who the close contacts are of that first case, and vaccinates just those close contacts, and not the entire city or suburb,” Dr. David Freedman, professor emeritus of infectious diseases at the University of Alabama, was quoted by Time magazine as saying.
NASDAQ:SIGA
by BlackBull_Markets
INNO Trades Steady, Outperforms the CSE25 and HMMJ Marijuana ETF$INNO.CN stock grew by +3.39% on Friday, stock opened at $0.590 and closed at $0.610, meanwhile price action is working above 20 EMA in daily chart that shows stock is bullish in nature and MACD is also showing strength in stock. RSI is close to par, indicating that current share price is fairly valued. The market cap of the company is 159.073M, and its average 3mo volume is 52k. Last week amidst pronounced downturns in major markets and indexes, INNO continued to trade steadily, and outperformed the CSE25 Composite Index alongside the TSX's HMMJ Marijuana ETF. Despite serious background volatility, the legalization of recreational cannabis use in New Jersey and its steadily progressing R&D pipeline are clear bullish indicators for INNO's LT potential
CSE:INNO
by BiotechBrandon
PFE: Sell Zone is 58-60Pfizer's W-4 bottomed right in our "Buy Zone" and has bounced 10% since. I expect Pfizer to continue to climb up to the $58-60 level over the coming 2 weeks or so. After that, Pfizer will pull back for it's larger degree W-2, which should bring price back to about the $50 level. We will have more clarity on pullback targets once W-5 tops, most likely in our "selling zone". The point is, this is not an idea time to start a position. I will be selling covered calls against my shares of Pfizer when we reach the selling zone, and will be looking to add shares for about $50 sometime in Late May/Early June.
NYSE:PFELong
by TomDaSpankEngine
Mid-cap Pharma Company might get a booster dose.Mid-cap Pharma Company might get a booster dose? The 31,177.59 Cr. worth mid-cap Pharma company, Laurus Labs Ltd. gave a massive 96% CAGR (3yrs.) in the past. The share price of the company made a high of Rs. 723.55 after which it saw a downturn is now giving signals of its trend reversal to Bullish. The share price of the company made an 'inverted Head and Shoulders' pattern which is a bullish trend reversal pattern. Also, the share price might also see a 50 & 100 EMA crossover in the next 1-3 trading session which again makes it a positive for traders & investors. In clear words, the target for the share is 665 - 685, with a mid-term view of 2- 12 weeks. The stock might retest the level of 550 - 560 (precisely Rs. 555) which would also make it the ultimate support. Also, please consult your financial advisor before entering into any trade. This piece of knowledge is shared only for educational purposes. Thank You & keep learning!
NSE:LAURUSLABSLong
by GautamNegi
ARDS Covid-19 First-in-Class Antibody | +818% Analyst Rating ! Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Market Cap of only 32.605Mil 52 Week Range 1.89 - 8.47 I think this might be our 10X stock for 2022. Happy New Year!
ALong
by TopgOptions
2
QNRX Market Outperform Price Target !!Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome. My price target is the 12usd resistance.
NASDAQ:QNRXLong
by TopgOptions
4